Oral semaglutide improves heart function and blood flow in a pig model of coronary artery disease through AMPK pathway | Research

The takeaway

Oral semaglutide improved ejection fraction, myocardial perfusion, and capillary density in chronically ischemic pig hearts through AMPK-mediated endothelial protection and eNOS activation, independent of diabetes or obesity.

Direct cardiac healing
Oral semaglutide improved heart function and grew new blood vessels in ischemic pig hearts through AMPK pathway—independent of diabetes or weight loss

What the researchers found

Improved LVEF at rest and during pacing (both p significant). Increased myocardial perfusion to ischemic segments (p=0.008). Increased capillary density (p=0.008). AMPK pathway activation (p=0.005). eNOS upregulation (p=0.014). 8 treated vs 9 control pigs.

Why it matters

This is the first study proving oral semaglutide directly improves cardiac function and blood flow in ischemic hearts, independent of metabolic effects. This supports using semaglutide specifically for coronary artery disease, not just as a diabetes/obesity drug.

How the study worked

Yorkshire swine (n=17): ameroid constrictor on LCx → chronic ischemia. Oral semaglutide (1.5→3 mg) for 5 weeks vs no drug. Microsphere perfusion, pressure-volume loops, immunoblotting, immunohistochemistry.

What this study cannot tell us

Pig model (though highly translational). Small sample (17). Short treatment (5 weeks). Oral semaglutide doses may not match human exposure. No long-term outcomes.

How to read the evidence

Highly translational large animal study with rigorous methodology (microsphere perfusion, PV loops). Strong mechanistic evidence.

When this study was published

Published in 2025.

The bigger picture

This is paradigm-shifting: GLP-1 drugs may directly heal ischemic hearts by growing new blood vessels and improving existing blood flow, not just by managing risk factors. This could transform treatment for patients with angina refractory to current therapies.

Questions still open

Could semaglutide replace or complement revascularization for some patients?
Is the AMPK-eNOS mechanism sufficient to explain the perfusion improvement?
Would longer treatment produce more capillary growth?

Common questions

Can semaglutide help hearts with blocked arteries?

This pig study provides strong evidence that oral semaglutide directly improves blood flow to areas of the heart with blocked arteries. It increased both the heart's pumping ability and the number of tiny blood vessels supplying the ischemic area. These effects were independent of diabetes or obesity.

How does semaglutide improve heart blood flow?

Semaglutide activates the AMPK pathway in heart blood vessels, which in turn increases eNOS—an enzyme that produces nitric oxide. Nitric oxide dilates blood vessels, improves endothelial function, and promotes the growth of new capillaries, collectively restoring blood supply to ischemic heart muscle.

Read the original research

Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.

Arteriosclerosis, thrombosis, and vascular biology, 45(2), 285-297

View on PubMed ↗Publisher’s paper ↗

Citation

Stone, Christopher; Harris, Dwight D; Broadwin, Mark; Kanuparthy, Meghamsh; Nho, Ju-Woo; Yalamanchili, Keertana; Hamze, Jad; Abid, M Ruhul; Sellke, Frank W. (2025). Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.. Arteriosclerosis, thrombosis, and vascular biology, 45(2), 285-297. https://doi.org/10.1161/ATVBAHA.124.321850